For people living with fibrodysplasia ossificans progressiva (FOP), the body gradually forms bone in places where bone should not exist. This can severely restrict movement and progressively affect everyday life.
Pasatru (garetosmab-grts) is designed to help address this process by reducing new heterotopic bone formation and disease flare-ups in adults with FOP. Its approval provides another treatment option for a condition where therapeutic choices have historically been extremely limited.
As a treatment in the rare disease space, Pasatru will be important to monitor for its availability, adoption, and future relevance in clinical development.
